GXO Earnings

GXO reported its FY2025Q4 earnings on 2026-02-10, showcasing a revenue of 0.00 against an estimate of 3.00B, resulting in a 0% surprise. The EPS was 0, surpassing the expected 0.83 by 0% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following GXO's FY2025Q4 earnings announcement on 2026-02-10, the stock price moved by % on the day of the release. Over the subsequent five days, it saw a % change. Historically, GXO's stock price tends to shift by an average of +2.39% in the 10 days leading up to earnings and -0.06% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate GXO’s annual revenue to reach 3.00B, while the EPS is projected at 1.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Downward by -0.37% and EPS estimates Revise Downward by -1.47% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between GXO's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Downward by -0.37%, while EPS estimates moved Revise Downward by -1.47% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, GXO's stock price typically moves by +2.39% in the 10 days before its earnings and -0.06% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 1.00 and revenue of 3.00B.

The earnings call summary and Q&A highlight strong financial metrics, increased guidance, and promising developments in technology and AI. The NHS contract and Wincanton integration are expected to drive growth, with significant synergies anticipated. Despite some uncertainties in Q4 guidance, the overall sentiment is positive, with strategic focus on high-margin verticals and expansion in healthcare and AI. The raised full-year EBITDA guidance and robust sales pipeline further support a positive outlook for the stock price over the next two weeks.